Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Heterokaryotypic monozygotic twins discordant for Down syndrome (DS) are very rare, with an incidence estimated to be less than 1 over 7,000,000 pregnancy in the general population. Sharing the same genetic patrimony, except for an additional chromosome 21 for one of them, any gene-expression difference between them could be attributed only to the supernumerary chromosome 21 and not to polymorphic variability in the rest of the genome. The setting up of a prospective longitudinal study will offer the major advantage of allowing genetic and epigenetic comparisons between them and to obtain important information on the impact of the environment in which they live and grow up.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 4
Maximum Age: 11
Healthy Volunteers: t
View:

• Twins of a heterokaryotypic monozygotic pair discordant for DS

• Twins of a sex- and class of age-matched dizygotic pair discordant for DS,

• Sex- and class of age-matched patient with mosaic T21

• Subject's parents/legal representatives willing to give written informed consent.

• Subject and his/her parents/legal representatives must be able/willing to comply with the protocol.

• Subject covered by social welfare.

Locations
Other Locations
France
Institut Jérôme Lejeune
RECRUITING
Paris
Contact Information
Primary
Sophie Durand
sophie.durand@institutlejeune.org
0033156586300
Time Frame
Start Date: 2022-12-20
Estimated Completion Date: 2028-12-30
Participants
Target number of participants: 5
Treatments
Other: Down syndrome children
Two pairs of twins discordant for Down syndrome and 1 children with mosaic Down syndrome will be recruited. Blood, skin and feces samples will be specifically collected for the purpose of the study.
Related Therapeutic Areas
Sponsors
Leads: Institut Jerome Lejeune

This content was sourced from clinicaltrials.gov